| Literature DB >> 25330848 |
Nina Majlund Harder-Lauridsen1, Nina Marie Birk, Mathias Ried-Larsen, Anders Juul, Lars Bo Andersen, Bente Klarlund Pedersen, Rikke Krogh-Madsen.
Abstract
BACKGROUND: Obesity amongst children is a growing problem worldwide. In contrast to adults, little is known on the effects of controlled weight loss on components of the metabolic syndrome in children. The primary aim of the study was to evaluate the effects of a 20-week exercise and diet guidance intervention on body mass index (BMI) in a group of overweight children. Our hypothesis was an observed reduction in BMI and secondarily in body fat content, insulin insensitivity, and other components of the metabolic syndrome in the intervention group.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25330848 PMCID: PMC4287468 DOI: 10.1186/1471-2431-14-273
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Figure 1Design of the randomized controlled trial. CONSORT 2010 Flow Diagram [34] showing the number of children invited, enrolled, allocated, at Follow-Up, and in the analyses. *Children (age 7–10 years) at inclusion time in Høje Taastrup Municipality who were identified as overweight or obese by the ‘SundSkoleNettet’/‘The Healthy Schools Network’. **Children (age 7–10 years) at inclusion time who participated in the early evening information meetings.
Descriptive characteristics of the children at baseline
| Control group | Intervention group | P value | ||
|---|---|---|---|---|
| n | Baseline | Baseline | ||
| Girls | 37 |
|
| - |
| Age (years) | 37 | 8.7 (0.9) | 8.8 (0.9) | 0.8 |
| Birth weight (gram) | 35 | 3,634 (488.4) | 3,555 (417.0) | 0.6 |
|
| ||||
| Weight (kg) | 37 | 39.7 (8.1) | 44.6 (10.1) | 0.1 |
| BMI (kg/m2) | 37 | 21.0 (3.5) | 22.6 (3.8) | 0.2 |
| Overweight | 20 |
|
| 0.3 |
| Obese | 17 |
|
| 0.1 |
| zBMI | 37 | 1.8 (0.8) | 2.2 (0.8) | 0.1 |
| Waist (cm) | 35 | 79.2 (7.4) | 81.2 (8.9) | 0.5 |
| Hip (cm) | 35 | 80.7 (8.7) | 84.1 (8.2) | 0.2 |
| Waist-to-height ratio | 35 | 0.6 (0.1) | 0.6 (0.1) | 0.9 |
|
|
| |||
| Lean body mass (kg) | 23.1 (3.3) | 25.3 (4.3) | 0.1 | |
| Fat mass (kg) | 15.0 (5.4) | 17.6 (6.8) | 0.2 | |
| Body fat tissue percent (%) | 38.3 (7.1) | 40.2 (7.0) | 0.4 | |
| Android fat mass (kg) | 1.3 (0.5) | 1.7 (0.8) | 0.08 | |
| Gynoid fat mass (kg) | 2.9 (1.0) | 3.4 (1.2) | 0.2 | |
| Android/gynoid ratio | 0.4 (0.1) | 0.5 (0.1) | 0.05 | |
|
|
| |||
| Systolic (mmHg) | 101.9 (8.0) | 102.2 (8.9) | 0.9 | |
| Diastolic (mmHg) | 62.8 (7.7) | 62.0 (6.1) | 0.6 | |
| Heart Rate (beats/min) | 81.4 (13.6) | 79.7 (11.0) | 0.7 | |
|
| ||||
| Steps per day (maximum) | 31 | 14,313 (3,176) | 13,049 (2,783) | 0.3 |
| Modified Andersen fitness test (meter) | 37 | 689.6 (135.5) | 649.5 (173.9) | 0.4 |
| Jumping test (cm) | 37 | 22.9 (4.3) | 24.6 (6.3) | 0.4 |
Presented as mean (standard deviation) or total in the group (percentage of the group).
P value assessed by unpaired Student’s t-test.
zBMI, standardized BMI.
Descriptive characteristics of the explorative measurements at baseline
| Control group | Intervention group | P value | ||
|---|---|---|---|---|
| n | Baseline | Baseline | ||
|
| ||||
| HbA1c (mmol/mol) | 30 | 34.9 (2.8) | 34.9 (2.5) | 1.0 |
| | ||||
| Fasting glucose (mmol/L) | 30 | 4.3 (0.2) | 4.4 (0.3) | 0.2 |
| Fasting insulin (mmol/L) | 30 | 62.9 (38.5) | 67.7 (25.4) | 0.7 |
| 120 min (2 h) glucose (mmol/L) | 26 | 5.7 (1.1) | 5.6 (0.8) | 0.8 |
| Matsuda Index | 25 | 21.8 (12.4) | 13.0 (3.9) | P <0.05 |
| HOMA-IR | 30 | 1.7 (1.1) | 1.9 (0.7) | 0.6 |
| | 19 | 4.8 (0.4) | 5.3 (0.6) | P <0.05 |
|
| ||||
| Alanintransaminase (U/l) | 29 | 30.1 (21.2) | 26.8 (11.1) | 0.6 |
| Aspartattransaminase (U/l) | 29 | 33.0 (12.2) | 31.4 (5.2) | 0.7 |
| Thyrotropin (x10-3int.enh./l) | 30 | 2.6 (1.2) | 2.7 (0.9) | 0.6 |
| Triiodthyronin (nmol/l) | 30 | 2.8 (0.5) | 2.6 (0.3) | 0.3 |
| Thyroxin (nmol/l) | 30 | 107.1 (26.8) | 102.1 (18.9) | 0.6 |
| Total cholesterol (mmol/L) | 30 | 4.6 (0.6) | 4.3 (0.9) | 0.5 |
| LDL (mmol/L) | 30 | 2.7 (0.4) | 2.7 (0.8) | 0.9 |
| HDL (mmol/L) | 30 | 1.5 (0.4) | 1.4 (0.4) | 0.5 |
| Triglycerides (mmol/L) | 30 | 0.9 (0.8) | 0.7 (0.2) | 0.4 |
| Estradiol (pmol/L)# | 29 | 35 (30) | 28 (14) | 0.05 |
| Testosterone (nmol/L)# | 28 | 0.12 (0.0) | 0.12 (0.0) | 0.9 |
| Sex hormone-binding globulin (nmol/L)# | 29 | 62 (37) | 49 (33) | 0.4 |
| Follicle-stimulating hormone (IU/L)# | 29 | 1.11 (1.33) | 1.06 (0.81) | 0.9 |
| Luteinizing hormone (IU/L)# | 29 | 0.03 (0.12) | 0.03 (0.04) | 0.4 |
| IGFBP-3 (ng/mL)# | 29 | 4080 (1130) | 4695 (490) | 0.06 |
| Insulin-like growth factor 1 (ng/mL)# | 29 | 229 (131) | 244.5 (74) | 0.6 |
| Adiponectin (ng/mL)# | 26 | 19,547 (8,790) | 18,138 (5,740) | 0.5 |
| Leptin (pg/mL)# | 25 | 17,613 (27,432) | 26,399 (23,333) | 0.3 |
| Resistin (ng/mL)# | 26 | 7.0 (2.5) | 7.5 (2.1) | 0.3 |
| Visfatin (ng/mL)# | 23 | 0.34 (0.49) | 0.39 (0.62) | 0.9 |
Presented as mean (standard deviation) and P value assessed by unpaired Student’s t-test, or #median (interquartile range) and P value assessed by Wilcoxon rank-sum test.
Mean 48 h BG by CGMS, mean blood glucose measured in 48 h by continuous glucose monitoring system.
HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
IGFBP-3, Insulin-like growth factor-binding protein 3.
Delta changes in descriptive variables from baseline to follow up time point
| n | Control ∆adj | n | Intervention ∆adj | n | Intervention effect ∆adj | P value | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Weight (kg) | 18 | 1.9 (1.7; 2.1) | 19 | -1.9 (-2.1; -1.6) | 37 | -4.0 (-4.9; -3.0) | P <0.001 |
| BMI (kg/m2) | 18 | 0.3 (0.3; 0.4) | 19 | -1.6 (-1.7; -1.5) | 37 | -2.0 (-2.5; -1.5) | P <0.001 |
| zBMI | 18 | 0.07 (0.05; 0.08) | 19 | -0.43 (-0.44; -0.42) | 37 | -0.5 (-0.6; -0.4) | P <0.001 |
| Weight (kg) | 18 | 2.0 (1.4; 2.7) | 18 | -2.0 (-2.6; -1.3) | 36 | -4.0 (-4.9; -3.0) | P <0.001 |
| BMI (kg/m2) | 17 | 0.4 (0.0; 0.7) | 18 | -1.6 (-2.0; -1.3) | 35 | -2.0 (-2.5; -1.5) | P <0.001 |
| zBMI | 17 | -0.07 (-0.2; 0.2) | 18 | -0.44 (-0.5; -0.3) | 35 | -0.5 (-0.6; -0.4) | P <0.001 |
| Waist (cm) | 17 | -0.5 (-2.0; 0.9) | 18 | -5.3 (-6.7; -3.9) | 35 | -4.8 (-6.8; -2.8) | P <0.001 |
| Hip (cm) | 17 | -0.7 (-2.1; 0.6) | 18 | -5.3 (-6.6; -4.0) | 35 | -4.5 (-6.4; -2.6) | P <0.001 |
| Waist-to-height ratio | 17 | -0.01 (-0.02; 0.00) | 18 | -0.05 (-0.06; -0.04) | 35 | -0.03 (-0.05; -0.02) | P <0.001 |
|
|
|
|
| ||||
| Lean body mass (g) | 1,806 (1,352; 2,260) | 1,043 (584; 1,501) | -763 (-1,426; -101,1) | P <0.05 | |||
| Fat mass (g) | 711 (185; 1,238) | -2,733 (-3,261; -2,205) | -3,344 (-4,200; -2,689) | P <0.001 | |||
| Body fat tissue percent (%) | -0.4 (-1.5; 0.7) | -5.3 (-6.4; -4.2) | -4.9 (-6.5; -3.3) | P <0.001 | |||
| Android fat mass (g) | 53.8 (-33.8; 141.5) | -324.5 (-411.0; -237.9) | -378.3 (-503.6; -253.0) | P <0.001 | |||
| Gynoid fat mass (g) | 121.2 (5.0; 237.5) | -446.4 (-561.4; -331.5) | -567.7 (-732.8; -402.5) | P <0.001 | |||
| Android/gynoid ratio | 0.005 (-0.01; 0.02) | -0.044 (-0.06; -0.02) | -0.049 (-0.08; -0.02) | P <0.001 | |||
|
|
|
|
| ||||
| Systolic (mmHg) | 0.4 (-4.1; 5.0) | 2.3 (-2.2; 6.9) | 1.9 (-4.5; 8.4) | 0.6 | |||
| Diastolic (mmHg) | -0.2 (-5.1; 4.7) | -1.1 (-6.0; 3.7) | -0.9 (-7.8; 6.0) | 0.8 | |||
| Heart Rate (beats/min) | 1.5 (-2.8; 5.8) | -4.2 (-8.5; 0.1) | -5.7 (-11.8; 0.4) | 0.07 | |||
|
| |||||||
| Steps per day (maximum) | 14 | 2,760 (408; 5,111) | 13 | 4,705 (2,314; 7,096) | 27 | 1,946 (-1,140; 5,331) | 0.3 |
| Modified Andersen fitness test (meter) | 17 | 62.3 (26.4; 98.3) | 16 | 92.3 (55.3; 129.3) | 33 | 30.0 (-22.0; 81.8) | 0.3 |
| Jumping test (cm) | 18 | 1.9 (-0.3; 4.1) | 17 | 4.0 (1.8; 6.2) | 35 | 2.1 (-1.1; 5.2) | 0.2 |
P values are representing the intervention effects (the difference in change between the groups) adjusted for the respective baseline values (95% confidence intervals).
P values assessed by ANCOVA.
zBMI, standardized BMI.
Figure 2The glucose metabolism measured by oral glucose tolerance test. The area under curve is shown as bar graphs, while the response over time is shown as curves for plasma insulin (A) and glucose (B), respectively. P values are representing the intervention effects (the difference in change between the groups) adjusted for the respective baseline values (95% confidence intervals as error bars on bar graphs and Standard Error of the Mean as error bars on curves). ★, P <0.05; , not significant.
Delta changes in the explorative measurements from baseline to follow up time point
| n | Control ∆adj | n | Intervention ∆adj | n | Intervention effect ∆adj | P value | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| HbA1c (mmol/mol) | 12 | -0.3 (-0.8; 0.1) | 14 | -0.5 (-0.9; -0.1) | 26 | -0.2 (-0.8; 0.5) | 0.6 |
| | |||||||
| Fasting glucose (mmol/L) | 14 | 0.1 (-0.1;0.3) | 14 | 0.1 (-0.1; 0.2) | 28 | 0.0 (-0.3; 0.3) | 0.4 |
| Fasting insulin (mmol/L) | 13 | -4.7 (-17.6; 8.2) | 12 | -13.4 (-26.7; -0.1) | 25 | -8.7 (-27.4; 10.0) | 0.3 |
| 120 min (2 h) glucose (mmol/L) | 10 | 0.6 (-0.1; 1.3) | 13 | 0.1 (-0.5; 0.7) | 23 | -0.5 (-1.4; 0.4) | 0.3 |
| Matsuda Index | 9 | -3.4 (-10.2; 3.5) | 12 | 7.4 (1.9; 13.0) | 21 | 10.8 (1.4; 20.2) | P <0.03 |
| HOMA-IR | 13 | 0.1 (-0.5; 0.3) | 12 | -0.4 (-0.8; 0.1) | 25 | -0.3 (-0.9; 0.3) | 0.3 |
| Mean 48 h BG (mmol/L) by CGMS | 7 | 0.1 (-0.6; 0.9) | 9 | -0.3 (-1.0; 0.4) | 16 | -0.4 (-1.5; 0.7) | 0.4 |
|
| |||||||
| Alanintransaminase (U/l) | 12 | -7.9 (-12.6; -3.3) | 14 | -9.1 (-13.3; -4.8) | 26 | -1.1 (-7.4; 5.2) | 0.7 |
| Aspartattransaminase (U/l) | 12 | -2.0 (-5.1; 1.1) | 14 | -2.9 (-5.8; 0.0) | 26 | -0.9 (-5.1; 3.3) | 0.7 |
| Thyrotropin (x10-3int.enh./l) | 14 | 0.1 (-0.4; 0.6) | 14 | 0.3 (-0.1; 0.8) | 28 | 0.2 (-0.5; 0.9) | 0.5 |
| Triiodthyronin (nmol/l) | 14 | -0.2 (-0.3; 0.0) | 14 | -0.2 (-0.4; -0.1) | 28 | -0.1 (-0.3; 0.1) | 0.5 |
| Thyroxin (nmol/l) | 14 | 0.8 (-3.9; 5.5) | 14 | -0.6 (-5.3; 4.1) | 28 | -1.4 (-8.0; 5.3) | 0.7 |
| Total cholesterol (mmol/L) | 14 | -0.3 (-0.5; 0.0) | 14 | -0.5 (-0.8; -0.3) | 28 | -0.3 (-0.6; 0.0) | 0.07 |
| LDL (mmol/L) | 14 | -0.1 (-0.3; 0.1) | 14 | -0.4 (-0.6; -0.2) | 28 | -0.3 (-0.6; 0.0) | 0.06 |
| HDL (mmol/L) | 14 | 0.1 (0.0; 0.1) | 14 | 0.0 (-0.1; 0.1) | 28 | -0.1 (-0.2; 0.1) | 0.4 |
| Triglycerides (mmol/L) | 14 | -0.1 (-0.2; 0.0) | 14 | -0.3 (-0.4; -0.1) | 28 | -0.2 (-0.3; 0.0) | 0.1 |
| Estradiol (pmol/L) | 13 | -11.8 (-22.4; -1.2) | 13 | -14.8 (-25.5; -4.1) | 26 | -3.0 (-18.6; 12.5) | 0.7 |
| Testosterone (nmol/L) | 12 | 0.0 (0.0; 0.1) | 13 | 0.0 (0.0; 0.1) | 25 | 0.00 (-0.1; 0.1) | 1 |
| Sex hormone-binding globulin (nmol/L) | 13 | 4.2 (-2.4; 10.8) | 13 | 17.0 (10.5; 23.5) | 26 | 12.9 (3.5; 22.3) | P <0.01 |
| Follicle-stimulating hormone (IU/L) | 13 | 0.1 (-0.2; 0.3) | 13 | 0.0 (-0.3; 0.2) | 26 | -0.1 (-0.4; 0.3) | 0.7 |
| Luteinizing hormone (IU/L) | 13 | 0.0 (-0.1; 0.3) | 13 | 0.0 (-0.2; 0.2) | 26 | -0.1 (-0.3; 0.2) | 0.5 |
| IGFBP-3 (ng/mL) | 13 | -73.2 (-233.5; 87.0) | 13 | -124.5 (-291.0; 42.0) | 26 | -51.3 (-293.0; 190.4) | 0.7 |
| Insulin-like growth factor 1 (ng/mL) | 13 | 49.8 (15.1; 84.5) | 13 | 4.4 (-30.2; 39.1) | 26 | -45.4 (-94.5; 3.8) | 0.07 |
| Adiponectin (ng/mL) | 12 | -1,693 (-3,143; -242) | 13 | 595 (-801; 1,990) | 25 | 2,287 (254; 4,320) | P <0.05 |
| Leptin (pg/mL) | 11 | -7,803 (-15,402; -205) | 14 | -14,374 (-21,069; -7,679) | 25 | -6,570 (-16,944; 3,803) | 0.2 |
| Resistin (ng/mL) | 12 | -0.4 (-0.9; 0.1) | 14 | -0.6 (-1.0; -0.1) | 26 | -0.2 (-0.8; 0.5) | 0.6 |
| Visfatin (ng/mL) | 10 | 0.0 (-0.3; 0.2) | 11 | 0.2 (-0.1; 0.4) | 21 | 0.2 (-0.2; 0.5) | 0.3 |
P values are representing the intervention effects (the difference in change between the groups) adjusted for the respective baseline values (95% confidence intervals).
P values assessed by ANCOVA.
Mean 48 h BG (mmol/L) by CGMS, mean blood glucose measured in 48 h by continuous glucose monitoring system.
HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IGFBP-3, Insulin-like growth factor-binding protein 3.
Figure 3Physical activity measured by pedometer. Weighted mean steps per day (A) and mean minimum steps registered on the least active single day (B) registered by Pedometer. P values are representing the intervention effects (the difference in change between the groups) adjusted for the respective baseline values (95% Confidence intervals as error bars). ★, P <0.05; ★★, P <0.01.